Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ivonescimab in High-Risk, Localized RCC
NCT07226544Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in renal cell carcinoma (RCC), sponsored by City of Hope. Started Aug 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07226544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226544.